

Active substances set

Search phrase: Liver cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Liver cancer

Regorafenib

Regorafenib is indicated as monotherapy for the treatment of adult patients with - hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

 **NO REIMBURSEMENT**
 **ESMO**

Cabozantinib

Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

 **NO REIMBURSEMENT**
 **ESMO**

Ramucirumab

Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.

 **NO REIMBURSEMENT**
 **ESMO**



Atezolizumab

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

 **NO REIMBURSEMENT**
 **ESMO**



Sorafenib

Sorafenib is indicated for the treatment of hepatocellular carcinoma.

 **FULL REIMBURSEMENT**
 **ESMO**

Lenvatinib

Lenvatinib is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

 **FULL REIMBURSEMENT**
 **ESMO**

